Windlas Biotech

WINDLAS · NSE

— · —

₹1,096.25

Closing price — 29 Sept 2026

Market cap ₹2,320 Cr · EPS ₹32.15

Valuation

Blended fair value using DCF and peer comparison methods.

See if Windlas Biotech is undervalued

Unlock intrinsic value for 4,800+ Indian stocks — free.

The intrinsic value shown is an algorithmic estimate based on publicly available financial data — including DCF analysis, peer comparison, and historical financials. It is not a research report, investment advice, or a recommendation to buy, sell, or hold any security. Stock valuations involve uncertainty and may differ significantly from market prices. Please consult a SEBI-registered investment adviser before making any investment decision.

Peer comparison

How this company stacks up against sector peers on valuation and quality metrics.

Branded generics & specialty pharma · 8 peers · sector medians shown

Better than medianWorse than median

Company	Mkt Cap	P/E	P/B	EV/EBITDA	ROE	Net Margin	Rev CAGR 3y
Windlas Biotech WINDLAS · you	₹2,348 Cr	34.5×	4.8×	—	14.1%	0.1%	—
Sector median	—	37.4×	3.8×	20.4×	12.5%	11.4%	14.7%
NATCO Pharma NATCOPHARM	₹15,503 Cr	11.0×	1.7×	10.9×	15.4%	34.8%	14.6%
Jubilant Pharmova JUBLPHARMA	₹15,442 Cr	38.2×	2.1×	15.3×	5.6%	4.8%	9.6%
Marksans Pharma Limited MARKSANS	₹13,495 Cr	32.9×	4.5×	20.7×	13.8%	14.2%	16.8%
CORONA Remedies Limited CORONA	₹12,727 Cr	64.4×	16.0×	46.6×	24.8%	13.2%	16.6%
Sanofi Consumer Healthcare India Limited SANOFICONR	₹10,285 Cr	45.5×	28.4×	31.4×	62.5%	27.3%	—
Strides Pharma Science Limited STAR	₹8,923 Cr	36.7×	2.5×	—	6.9%	0.1%	—
Medplus Health Services Limited MEDPLUS	₹7,968 Cr	45.5×	5.1×	12.1×	11.1%	3.2%	14.8%
Aarti Pharmalabs Limited AARTIPHARM	₹7,617 Cr	35.9×	3.0×	20.4×	8.2%	9.6%	-2.2%

Peer comparison verdict

Windlas is fairly valued relative to sector peers — trading near the sector median on key multiples (P/E ~37.4×, EV/EBITDA ~20.4×). Focus on execution quality and earnings trajectory from here.

Business quality

Valuation

P/E ratio

34.1×

P/B ratio

—

EV/EBITDA

—

Price/Sales

—

Returns

ROE

14.1%

ROCE

—

ROA

—

Growth

Revenue CAGR (3yr)

—

EPS CAGR (3yr)

—

Efficiency

Asset turnover

—

FCF yield

—

Dividend yield

—

Liquidity & Solvency

Debt / Equity

—

Debt / EBITDA

—

Interest coverage

—

Current ratio

—

Quick ratio

—

Financial health

Piotroski F-Score, Altman Z-Score, and key solvency ratios.

Financial health data is not yet available for this company.

Full financial data

Charts and annual statements for income, balance sheet and cash flow.

Income trend

Revenue, profit and margin trends over time.

Income statement data is unavailable for this company.

Cash flow

Where cash comes from and where it goes.

Cash flow data is not yet available for this company.

Balance sheet

Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.

Balance sheet data is not yet available for this company.

Numbers are illustrative — order-of-magnitude correct. For precise figures, refer to the company's annual report on BSE/NSE.

Shareholding pattern

Who owns this company and how that has changed.

Shareholding data is not yet available for this company.